Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Philip Philip, MD, talks about treating a newly diagnosed stage 4 pancreatic cancer patient

Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, talks about some considerations when treating a newly diagnosed stage 4 pancreatic cancer patient

Published: 24 January 2017

Recent Videos: ASCO GI Conference Coverage

video

Steven J. Cohen, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients

Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center ...

video

Steven J. Cohen, MD, outlines the results of the Checkmate 142 study in mCRC patients

Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center ...

video

Michael Soulen, MD, tells us about significant data coming out of the tumor board at ASCO GI 2018

Dr. Soulen, Professor of Radiology, Hospital of the University of Pennsylvania, Professor of Radiology in Surgery, Penn Medicine, shares significant ...

video

Michael Soulen, MD, discusses the most compelling presentations from ASCO GI 2018

Dr. Soulen, Professor of Radiology, Hospital of the University of Pennsylvania, Professor of Radiology in Surgery, Penn Medicine, offers his ...

video

Michael Soulen, MD, on the practice changing potential of data presented at his ASCO GI tumor board

Dr. Soulen, Professor of Radiology, Hospital of the University of Pennsylvania, Professor of Radiology in Surgery, Penn Medicine, elaborates on ...

video

Michael Soulen, MD, compares the possible benefits of retrospective vs. prospective trials

Dr. Soulen, Professor of Radiology, Hospital of the University of Pennsylvania, Professor of Radiology in Surgery, Penn Medicine, considers the ...

video

Steven J. Cohen, MD, on how to dose patients receiving regorafenib as a result of the ReDOS study

Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center ...

video

Steven J. Cohen, MD, considers the improvement in duration of therapy examined in the ReDOS study

Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center ...

video

Steven J. Cohen, MD, regarding combination atezolizumab + cobimetinib in mCRC patients

Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center ...

video

Steven J. Cohen, MD, describes how tumor sidedness impacts treatment decisions in mCRC

Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center ...

Related Videos

video-image

Steven J. Cohen, MD, outlines the results of the Checkmate 142 study in mCRC patients

video-image

Steven J. Cohen, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients

video-image

Steven J. Cohen, MD, provides insight into sequencing and efficacy outcomes in 2nd line mCRC

video-image

Steven J. Cohen, MD, describes how tumor sidedness impacts treatment decisions in mCRC

video-image

Steven J. Cohen, MD, regarding combination atezolizumab + cobimetinib in mCRC patients

video-image

Steven J. Cohen, MD, considers the improvement in duration of therapy examined in the ReDOS study

video-image

Steven J. Cohen, MD, on how to dose patients receiving regorafenib as a result of the ReDOS study

video-image

Michael Soulen, MD, discusses the most compelling presentations from ASCO GI 2018

video-image

Michael Soulen, MD, compares the possible benefits of retrospective vs. prospective trials

video-image

Michael Soulen, MD, on the practice changing potential of data presented at his ASCO GI tumor board

video-image

Michael Soulen, MD, tells us about significant data coming out of the tumor board at ASCO GI 2018

video-image

Philip Philip, MD, PhD, FRCP, discusses the impact of the Checkmate 142 study on mCRC

video-image

Philip Philip, MD, PhD, FRCP, on the implications of the LAPACT study presented at ASCO 2018

video-image

Philip Philip, MD, PhD, FRCP, considers the impact of immunotherapy agents in pancreatic cancer

video-image

Philip Philip, MD, PhD, FRCP, regarding key unmet needs in pancreatic ductal adenocarcinoma

video-image

Nevena Damjanov, MD, shares the latest news in systemic therapy for advanced HCC at ASCO 2018

video-image

Nevena Damjanov, MD, on the use of pembrolizumab in HCC patients previously treated with sorafenib

video-image

Nevena Damjanov, MD, outlines the role of TACE with systemic therapy in HCC patients

video-image

David Ilson, MD, PhD, considers how to assess response in gastroesophageal cancer patients

video-image

Richard Kim, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

video-image

Scott Kopetz, MD, PhD, FACP, on the potential of binimetinib + immunotherapy in mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, regarding molecular profile matching in trials with mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC

video-image

Jeffrey Meyerhardt, MD, MPH, on dose escalation of regorafenib as a result of the ReDOS study

video-image

Jeffrey Meyerhardt, MD, MPH, discusses the length of adjuvant therapy for colorectal cancer patients

video-image

Jeffrey Meyerhardt, MD, MPH, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC

video-image

Jeffrey Meyerhardt, MD, MPH, considers the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Nevena Damjanov, MD, discusses current treatment options and sequencing TKIs in HCC

video-image

Nevena Damjanov, MD, considers the shortcomings of RECIST in measuring efficacy in HCC patients

video-image

Scott Kopetz, MD, PhD, FACP, explains how nivolumab is being incorporated into mCRC treatment

video-image

Scott Kopetz, MD, PhD, FACP, tells us about the outcomes of Checkmate 142 in mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, considers the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Scott Kopetz, MD, PhD, FACP, discusses the incidence of BRAF mutation in CRC patients

video-image

Richard Kim, MD, offers analysis of the RAINFALL study in metastatic gastric & GE junction cancer

video-image

Richard Kim, MD, discusses pembrolizumab as an effective agent in HCC management

video-image

Richard Kim, MD, considers the effectiveness of combination sorafenib and TACE in HCC patients

video-image

Richard Kim, MD, on the use and sequencing of TKIs in hepatocellular carcinoma (HCC)

video-image

David Ilson, MD, PhD, discusses what can be done to improve outcomes in esophageal adenocarcinoma

video-image

David Ilson, MD, PhD, examines the results of the RAINFALL study at ASCO GI 2018

video-image

David Ilson, MD, PhD, on strategies for managing gastroesophageal patients after neoadjuvant therapy

video-image

David Ilson, MD, PhD, on how we can individualize treatment of gastroesophageal cancer patients

video-image

Howard Hochster, MD, outlines the results of the Checkmate 142 study in mCRC patients

video-image

Howard Hochster, MD, considers patient age and the OncotypeDX recurrence score in CRC

video-image

Andrew Zhu, MD, PhD, on the effectiveness of pembrolizumab in HCC patients treated with sorafenib

video-image

Andrew Zhu, MD, PhD, shares thoughts on treating adjuvant hepatocellular carcinoma (HCC) today

video-image

Laura Dawson, MD, FRCPC, on additional randomized studies of external beam radiation

video-image

Laura Dawson, MD, FRCPC, tells us about the results of the START study

video-image

Laura Dawson, MD, FRCPC, discusses the design of the START study in HCC

video-image

Laura Dawson, MD, FRCPC, provides some background on hepatocellular carcinoma (HCC)

video-image

Alan Venook, MD, outlines the role of liquid biopsy in gastrointestinal cancers

video-image

Alan Venook, MD, considers how immunotherapy is being integrated into CRC treatment algorithms

video-image

Alan Venook, MD, on the impact of dose escalation of regorafenib in mCRC patients

video-image

Alan Venook, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients

video-image

Alan Venook, MD, explains how tumor sidedness affects therapeutic choice

video-image

Khaldoun Almhanna, MD, MPH, offers opinion on the best way to manage early gastric cancer

video-image

Khaldoun Almhanna, MD, MPH, discusses the risk factors to watch for gastroesophageal cancer

video-image

Kenneth Wang, MD, offers opinion on approaches to treating esophageal cancer

video-image

Kenneth Wang, MD, on managing esophageal cancer patients who have completed neoadjuvant therapy

video-image

Kenneth Wang, MD, on how to assess response in esophageal cancer and utilize the information

video-image

Howard Hochster, MD, elaborates on how tumor sidedness affects therapeutic choice in mCRC patients

video-image

Howard Hochster, MD, on the ReDOS study, regorafenib, and the importance of duration of therapy

video-image

Andrew Zhu, MD, PhD, shares the latest in systemic therapy for advanced HCC at ASCO GI 2018

video-image

Andrew Zhu, MD, PhD, on how we diagnose and assess response in HCC patients

video-image

Khaldoun Almhanna, MD, MPH, on surveillance and the management of gastroesophageal cancer

video-image

Kenneth Wang, MD, considers how staging esophageal cancer has changed and improved

video-image

Howard Hochster, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

video-image

Philip Philip, MD, reflects on the impact of PEGPH20 in met pancreatic cancer